SCHEMBL7186707

SCHEMBL7186707

Cc1cc(C(C)(C)C)cc(C)c1C(=O)Pc1ccc(OCc2ccccc2)cc1.[LiH]

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 3/20 0.50
RXRA P19793 1/20 0.50
RXRB P28702 1/20 0.50
NR4A1 P22736 2/20 0.46
NR4A3 Q92570 2/20 0.46
MAOB P27338 1/20 0.45
PPARG P37231 4/20 0.44
PTGS1 P23219 2/20 0.44
PTGS2 P35354 2/20 0.44
LMNA P02545 1/20 0.44
CYP1A2 P05177 1/20 0.44
SLC6A2 P23975 1/20 0.44
CYP2C19 P33261 1/20 0.44
SLC6A3 Q01959 1/20 0.44
HIF1A Q16665 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
ALOX5 P09917 2/20 0.44
FFAR1 O14842 3/20 0.44
FFAR4 Q5NUL3 2/20 0.44
TSPO P30536 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7182912 0.89 TSPO (0.51) NR4A2NR4A1NR4A3MAOBPTGS1
SCHEMBL7185160 0.87 FFAR1 (0.50) NR4A2NR4A1NR4A3MAOBPTGS1
SCHEMBL7188222 0.86 NR4A2 (0.47) NR4A2RXRARXRBNR4A1NR4A3
SCHEMBL7185643 0.85 MAOB (0.46) NR4A2NR4A1NR4A3MAOBPTGS1
SCHEMBL7189943 0.84 NR4A2 (0.46) NR4A2RXRARXRBNR4A1NR4A3
SCHEMBL7190536 0.84 MRGPRX4 (0.45) NR4A2RXRARXRBNR4A1NR4A3
SCHEMBL7183728 0.84 SRD5A2 (0.39) PPARGPTGS1LMNAFFAR1MEN1
SCHEMBL7175718 0.84 EPHX2 (0.45) NR4A2RXRARXRBLMNACYP1A2
Lithium SCHEMBL7189947 0.82 NR4A2 (0.46) NR4A2RXRARXRBNR4A1NR4A3
SCHEMBL7180014 0.82 RXRB (0.39) RXRARXRBPPARGLMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 NR4A2 1314/4885RXRA 2745/4885RXRB 3027/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 NR4A2 1389/4885RXRA 2809/4885RXRB 3240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.